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Direct attenuation of West Nile (WN) virus strain NY99 for the purpose of vaccine development is not
feasible due to its high virulence and pathogenicity. Instead, we created highly attenuated chimeric virus
W1806 with the serological identity of NY99. To further attenuate W1806, we investigated effects of
mutations found in Japanese encephalitis virus vaccine SA14-14-2. WN viruses carrying all attenuating
mutations lost infectivity in mammalian, but not in mosquito cells. No single reversion restored infec-
tivity in mammalian cells, although increased infectivity in mosquito cells was observed. To identify a
subset of mutations suitable for further attenuation of W1806, we analyzed effects of E138K and K279M
changes on virulence, growth properties, and immunogenicity of derivatized W956, fromwhich chimeric
W1806 inherited its biological properties and attenuation proﬁle. Despite strong dominant attenuating
effect, introduction of only two mutations was not sufﬁcient for attenuating W1806 to the safety level
acceptable for human use.
& 2015 Elsevier Inc. All rights reserved.Introduction
The high virulence and pathogenicity of West Nile (WN) virus
strain NY99, which now has established its presence on the
American continent, makes highly unlikely direct attenuation of
the circulating strain for the development of a corresponding live
vaccine. Instead, we devised a different approach for the design of
a human attenuated West Nile vaccine (Yamshchikov, 2015). We
created a chimeric WN virus designated W1806 (Borisevich et al.,
2006), which combines a highly attenuated proﬁle, excellent
growth properties, and the high immunogenicity and protective
efﬁcacy against an aggressive challenge with wild type NY99.
Further attenuation of this virus to the safety level acceptable for a
human vaccine appears more feasible. Lastly, we chose to develop
the vaccine in a novel infectious DNA (iDNA) format (Borisevich
et al., 2006; Yamshchikov et al., 2001a).
WN virions are composed of a single-stranded (þ)RNA genome
of about 11,000 nt and three structural proteins C, prM/M, and E.
Flavivirus genomic RNA is the only virus-speciﬁc mRNA in infectedkov).cells and encodes a single ORF. A large precursor is processed into
structural and nonstructural proteins arranged in the order C-prM-
E-NS1-NS2A-NS2B-NS3-NS4A-2K-NS4B-NS5, where prM is an M
precursor, and NS1 through NS5 represent nonstructural proteins
(Rice, 1996). The prM, E, and NS1 proteins of many ﬂaviviruses,
including WN virus, are glycosylated, although non-glycosylated
WN strains have been identiﬁed as well (Beasley et al., 2001;
Berthet et al., 1997; Wengler et al., 1985). The chimeric W1806
virus carries genes of the prM and E proteins of the NY99 strain in
the viral vector backbone derived from highly attenuated isolate
W956 (Yamshchikov et al., 2004, 2001b). As the prM and E pro-
teins are major ﬂavivirus immunogens and the majority of the
virulence and pathogenicity determinants of NY99 are localized in
its nonstructural region (Borisevich et al., 2008; Guo et al., 2005;
Keller et al., 2006; Liu et al., 2005; Munoz-Jordan et al., 2005;
Samuel and Diamond, 2005; Scholle and Mason, 2005; Setoh et al.,
2015), the derived chimeric virus carries the serological identity of
NY99 without inheriting its high virulence and pathogenicity. We
believe chimeric W1806, which encodes only West Nile virus
proteins, is a better choice for the development of a West Nile
vaccine than heterologous chimeric viruses, such as based on
YF17D vaccine ChimeriVax-WN (Arroyo et al., 2004) or based on
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Since the majority of epitopes inducing cell-mediated immunity to
ﬂaviviruses are associated with ﬂavivirus non-structural proteins
NS1 through NS5 (Aberle et al., 2005; Anraku et al., 2002; Mla-
dinich et al., 2012; Yauch et al., 2010), the heterologous chimeric
WN vaccines would likely induce cell mediated immune response
that is largely irrelevant to protection against or clearance of WN
infection.
For the development of a safe human vaccine, we adopted
criteria reported earlier (Arroyo et al., 2004; Monath et al., 2006),
in which the acceptable for a human vaccine safety level was
deﬁned as lack of mortality upon intracranial inoculation of adult
mice with 104 infectious units of the vaccine candidate. WN virus
belongs to the Japanese encephalitis (JE) serocomplex of ﬂavi-
viruses, which also includes Saint Louis encephalitis, Murray valley
encephalitis, and Kunjin viruses (Burke and Monath, 2001). The
viruses cluster into this group by serological relatedness and bio-
logical properties, which is further supported by their homology at
both the amino acid and nucleotide levels. This suggested a fea-
sible rational attenuation pathway (Monath et al., 2001) for the
W1806 strain. JE vaccine strain SA14-14-2 derived in China from a
virulent SA14 strain (Ni et al., 1995) is licensed for human use in
China and in a few other South Asian countries, although not in
the U.S. (Barrett, 1997). The molecular basis of SA14-14-2
attenuation is well established. Nine or 10 (depending on wt
strains taken for comparison, Table 1) amino acid differences in
the E protein distinguish virulent JE strains from attenuated vac-
cine SA14-14-2. Highly virulent NY99 shares with the wild type JE
strains the same amino acid residues at nine out of 10 attenuating
positions in the E protein. Our intention was to investigate if
amino acid changes found in E of the SA-14-14-2 vaccine, when
introduced in context of the highly attenuated W956 or W1806,
can yield an attenuated vaccine candidate with the safety proﬁle
acceptable for its use in humans. While earlier experiments were
performed using originally proposed (Yamshchikov et al., 2004)
vaccine candidate W956, the applicability of the conclusions to
attenuation of the more immunogenic W1806 vaccine candidate is
based on the high similarity of their biological properties, such as
kinetics of virus growth, virus yields, lack of cytopathic effect, and
the highly attenuated proﬁles (Borisevich et al., 2006; Yamshchi-
kov, 2015). In this report, we summarize the initial attempts of
rational attenuation of the W1806 vaccine precursor following this
approach.Results
Transfer of all SA14-14-2 attenuating mutations ablates infectivity of
WN virus
We tested the applicability of the proposed rational attenuation
approach by introduction of all 10 attenuating amino acid changes
into pCMVW956, which is an infectious DNA plasmid encoding the
W956 isolate. The presence of all mutations and lack of additional
unwanted changes were conﬁrmed by complete sequencing of the
W956 genome insert in the resulting plasmid pCMVW956(10m).Table 1
Differences shared by wild type JE and NY99.
Positiona 107 138 176 177 2
wt JE/SA14 L E I T E
NY99 L E Y T E
SA14-14-2 F K V A G
a JE protein E coordinates; GenBank #AAA81554.Transfection of either BHK or Vero cells with this iDNA produced
brightly ﬂuorescent cells 24 h after transfection (Fig. 1a and b) that
lasted 5–7 days. To our surprise, however, no further spread of
infection was observed, except for an occasional presence of WN-
positive daughter cells (Fig. 1b). Thus, introduction of all 10
mutations completely ablated the virus capability to establish
productive infection in susceptible mammalian cells. We did not
investigate whether this was due to improper assembly of virions,
their failure to exit from infected cells, or due to loss of the cap-
ability to infect new cells. However, spread of infection was
observed after transfection of mosquito C6/36 cells with the same
construct (Fig. 4c–f). Evidently, assembly of virions in, their egress
from, and the ability to infect mosquito cells were not ablated by
the changes. Attempts to determine virus titers in media collected
168 hpt (Fig. 4f) by cell-based ELISA on Vero or BHK cells, which
are normally used for WN virus titration, produced inconsistent
results with poorly reproducible positive signals at the lowest
dilutions. More consistent titration results, however, were
observed when cell-based ELISA was run using C6/36 cells, with
titers reaching 102–103 TCID50/ml. Because cell-based ELISA
detects viral antigen in infected cells, these results are consistent
with the inability of W956(10m) to infect mammalian cells and
agree with retention of residual infectivity toward mosquito cells.
The same outcome was observed when titration in BHK or Vero
cells was performed at 28 °C instead of normally used 37 °C, thus
ruling out the possibility that a temperature-sensitive defect
ablated the ability of virus to infect mammalian cells. We were
unable to concentrate virus using PEG precipitation followed by
centrifugation through a 20% sucrose cushion due to high loss of
viable virus as determined by titration in C6/36 cells. Since
unmodiﬁed W956 can be concentrated at least 10-fold using this
procedure, the higher loss of the W956(10m) viability may be
attributed to destabilizing effects of the amino acid changes on the
virion assembly.
RT-PCR and sequence analysis of RNA isolated from C6/36 cells
infected with W956(10m) as well as RNA extracted from the media
indicated that all 10 introduced mutations were present in the E
gene. No other changes were found (data not shown). We did not
analyze whether mutations in other genome regions have
emerged during virus replication in C6/36 cells that could com-
pensate for the dysfunction of mutated E, thereby enabling spread
of infection in C6/36 cells. Similarly, spread infection was com-
pletely ablated in mammalian, but not in mosquito, cells when all
10 mutations were introduced into protein E of chimeric W1806
(results not shown).
The inability of preparing virus samples with a practically
usable concentration and the evident lack of infectivity toward
mammalian cells precluded evaluation of W956(10m) virus
properties in animals. Indeed, maximum allowable volume for
intracranial (i.c.) inoculation of mice (for evaluation of neuro-
virulence) is 20 μl, which at the maximal concentration attained
168 hpt of C6/36 would deliver only 20 TCID50 or less. Although for
immunogenicity studies larger volumes can be delivered by
intraperitoneal (i.p.) route, this will be inevitably accompanied by
inoculation of large amounts of insect antigens accumulated in the
media over 7 days. The impact of immunization with a massive44 264 279 315 439 447
/G Q K A K G
Q K A K G
H M V R D
Fig. 1. Infectivity of pCMVW956(10m). (a) BHK cells 24 h post transfection (hpt), (b) Vero cells 48 hpt; and C6/36 cells (c) 48 hpt; (d) 96 hpt, (e) 144 hpt; (f) 168 hpt.
Table 2
NY99-speciﬁc immune response induced by pCMVW956(10m)a.
Mouse no. 4 wk post immunization 4 weeks post boost PRNTc Survivald
IgMb IgGb IgMb IgGb
1 320 80 20 320 0 yes
2 20 0 20 20 0 yes
3 80 0 0 0 0 no
4 1280 1280 640 2560 0 yes
5 640 80 1280 80 0 yes
6 320 640 320 640 0 yes
a Immunization and boost with 1 μg of pCMVW956(10m) using Gene Gun.
b Endpoint dilution titers with NY99 antigen.
c Endpoint dilution PRNT50 with NY99 virus.
d Survival after i.m. challenge with 1000 LD50 of NY99.
Fig. 2. Antigen-speciﬁc proliferation and IFNγ release. BALB/c, splenocytes harvested 3 weeks after immunization with 1 μg of CMVW956(10m). Stimulation index: [3H]
counts in response to antigen/[3H] counts in response to Vero antigen; IFNγ was determined by ELISA.
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this reason, we decided to use direct inoculation of corresponding
iDNA. 2–3 day old suckling mice did not exhibit any symptoms
after i.c. inoculation with 1 μg of pCMVW956(10m). This i.c. dose
of wt pCMVW956 kills 100% infant or adult mice within 4–6 days
(data not shown). Yet, adult mice inoculated intradermally (i.d.)
with 1 μg of pCMVW956(10m) using Gene Gun demonstrated
NY99-reactive IgM and IgG detectable by ELISA, which increased
after boost with the same dose by the same route (Table 2).
Although mice surviving infection with W956 normally develop
high titers of NY99-neutralizing antibodies (Yamshchikov et al.,
2004), NY99 neutralizing immunity was undetectable after
immunization with pCMVW956(10m) even after the boost indi-
cating lack of infection. Yet, 83% of immunized mice were pro-
tected against challenge with 1000 LD50 of NY99 (Table 2). The
high neuroinvasiveness of NY99 inevitably resulting in death ofinfected naïve animals precluded evaluation of immune response
to NY99 or its infectious DNA as a baseline for direct comparison.
Splenocytes from mice immunized with pCMVW956(10m)
demonstrated detectable antigen-speciﬁc proliferative responses
and IFNγ release after stimulation with the antigen prepared from
NY99-infected Vero cells (Fig. 2), although responses were sig-
niﬁcantly higher to stimulation with the authentic antigen pre-
pared from cells infected with W956.
Thus, introduction of all 10 amino acid changes yielded safe but
over-attenuated virus W956(10m). Despite the inability of the
virus to establish productive infection in cultured mammalian cells
(Vero and BHK), iDNA encoding W956(10m) was still capable to
induce detectable immune responses and signiﬁcant protection
against lethal challenge. Remarkably, the protective immune
response was observed at the dose much smaller than doses
routinely used with the conventional (non-replicating) DNA
Fig. 3. Infectivity of pCMVW1806(9m) carrying single reversions (r) in attenuating positions #1 through #10 (Table 1). C6/36 at 4 days post transfection (dpt), 40 .
Fig. 4. Growth of parent and mutant viruses. Vero cells were infected at MOI¼1.
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be suitable for the goal of the WN vaccine development since it
has yielded the over-attenuated virus.
No single reversion can restore infectivity of W1806(10m) in mam-
malian cells
As ﬁrst explanation of such unexpected outcome we suggested
that a single mutation from the set may have caused a much stronger
disturbance of the E protein functionality than it could be expected
from the overall homology between WN and JE viruses (Kanai et al.,
2006; Nybakken et al., 2006). To test this hypothesis, we performed
systematic scanning of individual amino acid changes in the context of
W1806(10m) protein E. This was completed by reversion of a single
amino acid change back to the wild type leaving the other nine
changes in place. That is, changes 1 through 10 (Table 1) have been
reverted to the corresponding wild type residue one at a time in
pCMVW1806(10m) yielding constructs pCMVW1806(*2345678910),
pCMVW1806(1*345678910), pCMVW1806(12*45678910), and so on
(reversions are labeled by an asterisk). For brevity, these single
reversions are further referred to as #1r, #2r, #3r, respectively, and so
on. The resulting iDNA plasmids after veriﬁcation by sequencing were
transfected into Vero cells followed by incubation at 37 °C in the
growth medium for up to six days with subsequent immunostaining
to detect WN antigen-positive cells. Similarly to pCMVW1806(10m),
only single or occasional paired antigen-positive cells were observed
in Vero up to 6 days post transfection (data not shown) indicating thatno single reversion was able to restore the infectivity of the mutated
viruses in mammalian cells.
In mosquito C6/36 cells, however, effects of each attenuating
change on the infectivity of virions were clearly discernible
(Fig. 3). Reversions at positions #1, #2, #7, and to a lesser extent at
position #6, noticeably improved the infectivity of the mutated
viruses. Reversions at positions #3, #4 and #9 also yielded some
increase in the virus infectivity, although the effect was sub-
stantially less pronounced. Interestingly, reversions at positions #8
and #10 appeared to produce the opposite effect on the infectivity,
since only well separated single cells positive for the WN antigen
were observed at 4 dpt with pCMVW1806(#8r) and pCMVW1806
(#10r) in contrast to clearly distinguishable foci of positively
stained cells at 96 hpt with pW956(10m) (Fig. 1d).
In summary, no single reversions appeared to be sufﬁcient to
overcome the combined negative impact of the remaining nine
changes on the virus infectivity in mammalian cells.
Analysis of minimal sets of attenuating mutations
We further suggested that a smaller but optimal number of
mutations could achieve the optimal balance of safety and
immunogenicity. To test feasibility of this approach we analyzed
effects of only two mutations E138K and K279M (#2 and #7
respectively, Table 1) in the context of the W956 virus. These
positions are located in the β-sheet in the low pH reactive hinge,
which plays a crucial role in the fusogenic rearrangement of pro-
tein E and in virus entry (Bressanelli et al., 2004; Rey et al., 1995).
Following assembly and sequence veriﬁcation, the corre-
sponding pCMVW956 iDNA constructs were transfected into Vero
cells and mutant viruses W956(E138K), W956(K279M) and W956
(E138K,K279M) were harvested four days later. All viruses grew in
Vero (Fig. 4), BHK, and C6/36 cells (results not shown) without
detectable reversions after 2 passages as determined by sequen-
cing of the E gene. The growth properties of all viruses at Vero
passage 2 are shown in Fig. 4. Notably, dominant attenuating
mutation E138K displayed the greatest impact on the growth
properties of W956 reducing peak titers by three orders of mag-
nitude. The standalone K279M mutation affected virus growth as
well, albeit not as signiﬁcantly, but its combination with E138K
resulted in a slight improvement of the virus growth properties.
Table 3 shows different attenuating effects of single mutations
E138K and K279M, and double mutation set (E138K,K279M) in mice.
While the differences between mutants were obscured by the
Table 3
NY99-speciﬁc immune response induced by single and double mutant pCMVW956 constructs.
Needle, i.m.a Gene Gun, i.d.b
S1/T(%)c ELISAd PRNT50e S2/S1f S1/Tc ELISAd PRNT50e S2/S1 f
pCMVW956 1 μg 3/6 (50) 128000 640 3/3 0/6 (0) N/A N/A N/A
100 ng 6/6 (100) 128000 320 6/6 5/6 (83) 128000 1280 5/5
pCMVW956 (E138K) 1 μg 6/6 (100) 16000 80 6/6 6/6 (100) 128000 640 6/6
100 ng 6/6 (100) 16000 80 6/6 6/6 (100) 128000 320 6/6
pCMVW956 (K279M) 1 μg 6/6 (100) 128000 320 6/6 2/6 (33) 128000 320 2/2
100 ng 6/6 (100) 128000 160 6/6 4/6 (66) 128000 160 4/4
pCMVW956 (E138K,K279M) 1 μg 6/6 (100) 32000 20 6/6 6/6 (100) 32000 80 6/6
100 ng 6/6 (100) 128000 40 6/6 6/6 (100) 128000 320 6/6
a Tibialis anterior muscle.
b Abdominal skin.
c Survival after immunization, Survived/Total.
d With NY99 antigen.
e With NY99 virus.
f Survival after challenge with 50 LD50 of NY99.
Fig. 5. Neurovirulence of unmodiﬁed W1806 virus, unmodiﬁed and mutagenized
iDNA in mice. Mice were inoculated i.c. either with 104 TCID50 of W1806 (Vero pass
1) or with 1 μg of indicated iDNA in PBS and observed for signs of morbidity and
mortality. Severely morbid animals were euthanized and counted as dead.
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more efﬁcacious intradermal immunization using Gene Gun
revealed the higher residual virulence of the K279M derivative, as
judged by differences in mortality after immunization. Notably,
while double mutation (E138K,K279M) improved growth properties
of the derivative (Fig. 4), this was not accompanied by a dis-
cernible increase in mortality of the inoculated animals (Table 3).
All mice that survived immunization with mutagenized iDNA
developed readily detectable NY99 neutralizing immunity and
were completely protected against i.c. challenge with 50 LD50 of
NY99. This preliminary estimate showed that E138K produces more
attenuated virus with poorer growth characteristics than K279M,
but two mutations situated together produce an attenuated virus
with improved growth characteristics, which is immunogenic and
protective.
Next we tested whether the designed single and double mutant
attenuated viruses satisfy the adopted safety criteria mentioned
above. To minimize artifacts and uncertainty associated with
spontaneous possible reversions to the wild type amino acids at
positions #2 and #7 upon preparation of challenge virus stocks in
mammalian cells, we ﬁrst tested neurovirulence of encoded
mutant viruses after direct i.c. inoculation of corresponding
mutated iDNA. As shown in Fig. 5, i.c. inoculation of mice either
with 104 TCID50 of W1806 or with 1 μg of corresponding
pCMVW1806 iDNA resulted in 100% mortality of animals essen-
tially within the same time frame. This observation supported the
validity of direct intracranial iDNA inoculation for preliminary
evaluation of residual neurovirulence of mutant viruses encodedby modiﬁed iDNA. As shown in Fig. 5, either W1806(E138K) and
W1806(E138K,K279M) viruses still possess an unacceptably high
residual neurovirulence and require further attenuation.Discussion
We conducted experiments described in this report to verify
the conceptual validity of the approach for rational attenuation of
the W1806 vaccine candidate to the adopted safety level accep-
table for a human vaccine. As demonstrated in Table 1, attenuated
W956 and virulent NY99 share the same amino acid residues in E
at positions characteristic for attenuated SA14-14-2. This agrees
well with the current understanding that the sequence of the E
protein per se does not include determinants of the high patho-
genicity of the NY99 strain. This also provided a strong supportive
rationale that immunogenicity of the attenuated W956 isolate,
which was originally suggested for the development of a human
West Nile vaccine (Yamshchikov et al., 2004), can be safely
increased by chimerization with the NY99 envelope protein genes.
However, the NY99 envelope protein is glycosylated, but the W956
envelope protein carries a four amino acid deletion encompassing
the entire glycosylation site (NYST). Although glycosylation of E
was shown to increase virulence of lineage 1 WN strains (Beasley
et al., 2005; Shirato et al., 2004), this effect most likely can be
attributed to a higher infectivity of glycosylated virions and more
effective virus spread. We concluded that from comparison of
growth properties of glycosylated NY99 and chimeric derivatives
of NY99 and W956 (Borisevich et al., 2006). In chimeric virus
W1806 glycosylation of NY99 protein E was ablated by NYS-SYS
mutation, which was shown to be stable against reversion (Bor-
isevich et al., 2006). Both parent W956 and chimeric W1806 dis-
played essentially the same growth properties and attenuation
proﬁles, although W1806 appeared even more attenuated in the
adult mouse model (Borisevich et al., 2006; Yamshchikov, 2015).
However, as demonstrated in Fig. 5, otherwise highly attenuated
W1806 did not yet satisfy the adopted safety criteria causing rapid
100% mortality in mice after intracranial inoculation of the target
reference dose of 104 TCID50.
In the ﬁrst iteration of the rational attenuation approach deﬁned
above, we introduced in E of W956 all attenuating changes reported
for the E protein of SA14-14-2. To our surprise, this yielded a virus
that completely lost its infectivity toward mammalian cells. The
SA14-14-2 vaccine is manufactured using a primary mammalian
cell substrate (Barrett, 1997) implying that unlike WN virus the
attenuating changes in E did not ablate the growth properties of the
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adaptation of SA14-14-2 to Vero cells reported elsewhere (Hase et
al., 1993; Hong et al., 2001; Ni et al., 1995; Sil et al., 1992; Yang et al.,
2014; Yu, 2010) also supports this conclusion. As a ﬁrst explanation,
we suggested that the loss of infectivity was due to a dramatic
disturbance of the WN protein E functionality by a singular change,
which may have exerted a much stronger negative effect on the
functionality of E than it could be anticipated from the overall
homology between WN and JE viruses (Kanai et al., 2006; Nybak-
ken et al., 2006). In this regard, changes #3 (Y176V) and #10 (G447D)
stood out as possible candidates. While position 176 in E of wild
type JE viruses is occupied by aliphatic Ile, this position in the E
protein of both W956 and NY99 is occupied by aromatic amino acid
Tyr. If Tyr plays an important role, the functionality of WN protein E
could have been signiﬁcantly affected by its change to Val. Change
#10 (G447D) is reported in only one GenBank entry #AF315119
(unpublished), while other SA14-14-2 entries #AF495589 (unpub-
lished), #JN604986 (Song et al., 2012), #D90195 (unpublished), and
#AY033232 (Hong et al., 2001) agree on the presence of only
changes #1 through #9 summarized in Table 1. Out of these entries,
only two are referenced by published reports allowing to examine
details of the natural history of SA14-14-2 viruses characterized by
sequencing. Unfortunately, GenBank entries without published
references do not provide natural history details. Yet the origin of
entry #AF315119 (National Institute for the Control of Pharmaceu-
tical and Biological Products, Beijing, P. R. China) added a certain
credibility to the deposited information. For this reason mutation
#10 was included into consideration among other SA14-14-2
attenuating mutations. If mutation #10 is not present in commer-
cial lots of the SA14-14-2 vaccine, but its presence can negatively
affect virus growth, this would explain the observed lack of infec-
tivity toward mammalian cells.
However, systematic analysis of all introduced attenuation
changes revealed that neither of 10 single reversions can restore
the infectivity of mutated WN viruses toward mammalian cells,
although partial improvements of the infectivity toward mos-
quito cells have been observed after single reversions at positions
#1, #2, #6, and #7. While restoration of Tyr at position #3 did
improve somewhat the infectivity in mosquito cells, the effect
was not distinctive arguing for a minor functional importance of
position 176. Interestingly, reversion at position #10 appeared to
decrease the infectivity (Fig. 3) implying that the G447D change
could have improved growth characteristics of the corresponding
W1806(#10 r) virus. One may speculate that in some batches of
the SA14-14-2 vaccine, change #10 (G447D) may have been
selected as a compensatory improvement of vaccine virus growth
properties with or without discernible effects on the residual
virulence and safety of the vaccine. Whether incorporation ofFig. 6. Location of attenuating changes 1 through 8 (Table 1) on the three-dimensional
which includes approximately 400 N-terminal amino acids. Mutations #9 and #10 are loc
acids E anchoring the envelope protein in the viral membrane. The dimer is modeled w
the structure of the JE SA14-14-2 envelope protein.change #10 can offer any beneﬁts for the WN vaccine candidate
requires further studies.
Remarkably, iDNA encoding virus with the ablated infectivity
toward mammalian cells demonstrated readily detectable protec-
tive properties at far smaller doses than routinely used for DNA
vaccines in the mouse model. The observed protection in the
absence of detectable neutralizing antibodies suggests that the
protection was conferred upon the animals by other factors, for
example by cell-mediated immunity. Similar immune response
and protection despite undetectable neutralizing immunity was
observed with replicative-competent WN constructs (WN repli-
cons) that were incapacitated in virion assembly. In contrast,
replication-incompetent constructs with inactivated RNA poly-
merase NS5 did not induce detectable protective response at this
dose (1 μg) even after a boost (Seregin et al., 2006). This evidence
lends further support to our expectations that chimerization with
attenuated WN rather than with other distantly related attenuated
ﬂaviviruses will lead to a more efﬁcacious WN vaccine.
The results of the above studies led to the next iteration of the
rational attenuation scheme, in which we focused on identifying a
limited subset of attenuating changes that offers the optimal bal-
ance of safety, genetic stability, and immunogenicity. We began
with analyzing effects and applicability of the attenuating changes
#2 and #7. The E138K mutation (#2) was repeatedly demonstrated
to play a dominant role in maintenance of the attenuated pheno-
type (Aihara et al., 1991; Arroyo et al., 2001; Monath et al., 2002;
Sumiyoshi et al., 1992, 1995). Indeed, mice inoculated peripherally
with pCMVW956 (E138K) delivered either by i.m. bolus needle or by
i.d. Gene Gun inoculation did not show mortality or morbidity, yet
developed vigorous immune responses despite the signiﬁcantly
affected growth rate of the mutated virus. Interestingly, while the
(K279M) change also affected, albeit less signiﬁcantly, the virus
growth rate, this mutation has shown a slight enhancing effect on
virus growth properties when combined with the (E138K) mutation.
Yet, it did not result in a discernible increase in virulence in the
mouse model. The amino acid residue at the 279 position was
shown to inﬂuence neurovirulence and viscerotropism of the
ChimeriVax-JE vaccine candidate (Monath et al., 2002). While
reversion to the wild type (Met-Lys) increased vaccine neuro-
virulence, the revertant virus induced decreased systemic viremia
after vaccination. The latter evidence implies that reversion at pos.
279 reduced the replicative ﬁtness of the ChimeriVax-JE revertant.
This agrees well with Fig. 5, where single mutant W956(E138K)
displays decreased growth properties than double mutant W956
(E138K,K279M). Similar effect could be expected for chimeric W1806.
As shown in 3D representation of dimeric E of W1806 (Fig. 6),
which was modeled using coordinates of JE SA14-14-2 (Luca et al.,
2012), the attenuating change at position #1 (L107F) is located in or
immediately next to the fusogenic loop and changes at positionsmodel of the soluble WN E protein dimeric ectodomain (shown in one monomer),
ated in the stem-anchor region of E encompassing remaining 100 C-terminal amino
ith CLC Drug Discovery Workbench (QIAGEN, Aarhus A/S) using PDB entry 3P54 for
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reactive hinge (Bressanelli et al., 2004; Rey et al., 1995). These
structural elements are intimately involved in fusogenic rearran-
gement of protein E and membrane fusion accompanying virus
entry (Bressanelli et al., 2004; Rey et al., 1995), which agrees with
the enhancing effects of the reversions at positions #1, #2 and #7
on the virus infectivity. Moreover, positions 138 and 279 are
located in an apparent proximity to each other in such a way that
mutation (E138K) results in formation of electrostatically repulsive
pair Lys138–Lys279, which would affect the functionality of the pH
reactive hinge and thereby the fusogenic rearrangement of protein
E. Although mutation (K279M) slightly improves growth properties
of the W956 mutant perhaps by eliminating the repulsive force,
this does not seem to be sufﬁcient to ablate the strong attenuation
effect of the E138K mutation. This suggests that interaction of the
residue at position 138 with amino acids at other nearby positions
inﬂuences the functionality of the hinge, but this speculation
awaits an experimental proof. Such interaction would explain the
propensity of the E138K mutation for reversion, which was noticed
upon its original discovery in studies of JE virus attenuation
(Sumiyoshi et al., 1992, 1995). Although we did not detect this
reversion by sequencing of mutant viruses after two passages in
Vero cells, a much longer passage history is needed both in vitro
and in vivo to conclude about the genetic stability of the attenu-
ating mutations in the WN genome. We did not perform such
evaluation because neither single W956(E138K) nor double W956
(E138K,K279M) mutants met the target attenuation criteria. Inter-
estingly, a marginal attenuation enhancing effect of the SA14-14-2
subset involving positions #1 through #5 in the context of an
attenuated WN vaccine candidate (derived from W956) was also
reported earlier (Yu et al., 2008). Although it did not include sta-
bilizing change at position #7 (K279M), the set included changes at
positions #3 and #4, which are located on the opposite side of the
pH-reactive bridge (Fig. 6). Since the genetic stability of the virus
carrying ﬁve changes was not conﬁrmed by sequencing, one can-
not exclude that the rescued from the mutagenized infectious
clone virus population included partially reverted viruses. This
could improve overall growth properties of the rescued population
and skew its attenuation proﬁle toward higher neurovirulence.
In summary, the evidence reported in this study supports the
rationale that due to the strong dominant attenuating effect of
E138K and the possible stabilizing effect of K279M on retention of
the former, both mutations appear to be good candidates for
inclusion into the ﬁnal attenuation subset of mutations.Materials and methods
Viruses and cell culture
Vero cells (ATCC CRL-1586) and BHK-21 cells (Bredenbeek et al.,
1993) were maintained at 37 °C in a humidiﬁed atmosphere con-
taining 5% CO2 in Dulbecco's modiﬁed Eagle medium (DMEM)
supplemented with 5% FetalClone III (FCIII; Hyclone) and
1 antibiotic–antimycotic mixture (Fisher). All experiments
involving the use of WN strains were done in a BSL3 facility
according to the NIH guidelines.
Animals
10–12 g (3–4 weeks old) NIH Swiss or Swiss Webster outbred
female mice were purchased from Harlan Spraque-Dawley
(Indianapolis, IN). Mice were maintained in an ABSL3 facility
according to the NIH guidelines and used in experiments in
accordance with IACUC-approved animal protocols.Recombinant DNA, cloning, and bioanalytical procedures
were performed as described in previous reports (Borisevich et al.,
2008, 2006; Yamshchikov et al., 2004). Sequencing was performed
on ABI 310 or 3130xl Genetic Analyzers using manufacturer’s kits.
Alignments and sequence comparison was done using the Staden
package (Staden et al., 2000), CLC Genomic Workbench (Qiagen,
Aarhus, Denmark) and Geneious (Biomatters Ltd., Auckland, New
Zealand). Homology modeling was done with CLC Drug Discovery
Workbench (QIAGEN, Aarhus, Denmark) using PDB entry 3P54 for
the structure of the JE SA14-14-2 envelope protein.
Transfection and indirect immunostaining
Nearly conﬂuent (75–80%) monolayers of Vero, BHK or C6/36
cells prepared by seeding 24- or 12-well plate clusters the day
before the experiment with the appropriate number of cells in the
growth medium (DMEMþ10% FCS) were transfected with 0.5 μg
(24-well) or 1 μg (12-well) of iDNA-Lipofectamine 2000 com-
plexes prepared according to manufacturer's recommendations.
Five hours later the transfection media was removed, cells washed
twice with PBS and overlaid with the growth medium containing
1% methylcellulose. Following incubation in humidiﬁed 5% CO2 for
indicated time, the overlaid media were aspirated, cells washed
twice with PBS, ﬁxed in 80% acetone for 10 min at room tem-
perature, and dried.
For indirect immunoﬂuorescence, cells were incubated in PBS
supplemented with 0.1% Tween-20 and 1% BSA (blocking buffer)
for 1 h. WN antigens were detected by incubation with 1:1000
dilution of a WN hyperimmune ascites ﬂuid (prepared in house)
and, after washing, followed by 1 h incubation with 1:1000 dilu-
tion of a goat anti-mouse IgG ﬂuorescein conjugate (Sigma) in the
blocking buffer. After washing, dried cells were mounted in a
ﬂuorescence mounting buffer (Vector Laboratories) and observed
under an inverted ﬂuorescence microscope.
Virus titration by cell-based ELISA
Conﬂuent monolayers of Vero or C6/36 cells in 96-well clusters
were infected in triplicate with 50 μl of 10-fold serial dilutions of
tested virus preparations overnight in humidiﬁed 5% CO2. Next
morning, 100 μl of growth medium was added to each well and
clusters were returned to the incubator for one or two days. Fol-
lowing incubation, cells were washed with PBS, ﬁxed in 80%
acetone and dried as above. WN antigens were detected as
described above except a goat anti-mouse peroxidase conjugate
(Sigma) was used at 1:6000 dilution in the second step. Plate
clusters were developed using SureBlue 1-component TMB per-
oxidase substrate (KPL) following manufacturer instructions and
read on a microplate reader at 450 nm. The background signal
(calculated as averaged reading from 12 or 24 wells of mock-
infected cells plus 3 SD) was subtracted from all wells. TCID50
was calculated by the Reed & Muench method.
Immunization and challenge
Intramuscular immunization of mice with iDNA by needle
bolus injection was done as described earlier (Seregin et al., 2006),
Brieﬂy, mice were inoculated in the Tibialis anterior muscle with
1 μg of iDNA or a mixture of iDNA (10%) and pBR322 (90%) dis-
solved in PBS at the total DNA concentration of 50 μg/ml. For Gene
Gun immunization, 1 μg of iDNA or the iDNA–pBR322 mixture
were delivered intradermally into the shaved abdominal skin by a
single discharge of 1 μm gold particles coated with DNA as
recommended by the manufacturer (Bio-Rad). Peripheral chal-
lenge was done by inoculation of mice in the Tibialis anterior
muscle with 50 μl of PBSþ1% mouse serum containing 1000 i.m.
V. Yamshchikov et al. / Virology 487 (2016) 198–206 205LD50 of NY99. Intracerebral inoculation was done by inoculation of
mice with 20 μl of PBSþ1% mouse serum containing 50 i.c. LD50 of
NY99. Following the challenge, mice were observed for 14 days for
signs of neurological disease or death; diseased animals were
euthanized and counted as dead.Evaluation of immune response
Endpoint dilution titers of NY99-speciﬁc antibodies were evaluated
by ELISA as described earlier (Borisevich et al., 2006; Pereboev et al.,
2008; Seregin et al., 2006; Yamshchikov et al., 2005, 2004). Brieﬂy, 96-
well Immulon 4HB clusters (Fisher) were coated with the viral antigen
prepared from NY99 virus pelleted through the 20% sucrose cushion
and resuspended in 0.1% Triton-X100 in PBS supplemented with the
protease inhibitor cocktail (Fisher). Coated clusters were incubated
with serial 2-fold dilutions of immune sera followed by goat anti-
mouse (IgM or IgG) peroxidase conjugates at 1:6000 dilution in the
blocking buffer. Plates were developed using SureBlue 1-component
TMB peroxidase substrate (KPL) following manufacturer’s instructions
and read at 450 nm. The background signal (calculated as averaged
reading from 12 or 24 wells incubated with nonimmune mouse
serum plus 3 SD) was subtracted from all wells.
Evaluation of NY99 neutralizing antibodies was done using the
infectious focus reduction-neutralization test (FRNT) in the 96-
microplate format as described earlier (Borisevich et al., 2008).
Brieﬂy, NY99 virus prediluted to 1103 TCID50/ml was mixed with
equal volumes of serial 2-fold dilutions of immune sera in the
growth medium and incubated for 1 h at 37 °C. Fifty microliters of
each mixture were transferred in triplicate into wells of 96-well
plates with conﬂuent Vero monolayers and incubated for another
hour as above. The inocula were removed and replaced with
100 μl of the growth medium. The plates were incubated in the
CO2 incubator for 24 h and ﬁxed with 80% acetone as described
above. Foci of viral multiplication were visualized with a DAB
substrate (Vector Laboratories) after the following treatment
sequence (50 μl/well, 30 min each): 1:1000 dilution of NY99-
speciﬁc mouse hyperimmune antiserum, 1:500 dilution of bioti-
nylated horse anti-mouse IgG (HþL) (Vector Laboratories), 2 μg/
ml streptavidin, and 3.5 μg/ml biotinylated peroxidase. Endpoint
serum dilution titers were calculated as those providing 50%
reduction in the number of foci over control wells that contained
no immune serum and presented in the tables as more commonly
known PRNT50 values.Splenocyte proliferation and γ-interferon release assays
Proliferation and interferon release assays were performed
essentially as described earlier (Yamshchikov et al., 2005). Brieﬂy,
test and control antigens were prepared from lysates of Vero cells
infected with B956 or NY99, or from uninfected cells, and used at
1:200 to 1:500 dilution in PBS. Splenocytes were incubated in
triplicate in 96-well plate clusters with the antigens at 0.5–1106
per well. For the γ-interferon release assay, media were collected
three days later from each well, clariﬁed by centrifugation, and
concentration of released IFNγ was measured by ELISA with a
mouse anti-IFNγ monoclonal antibody pair from Pierce-Endogen
in accordance with the protocol supplied by the manufacturer. For
the proliferation assay, cells were labeled overnight with [3H]-
thymidine (1 μCi/well), harvested on ﬁlters and proliferation was
evaluated by [3H]-thymidine incorporation. Stimulation indices
were calculated as ratios of [3H]-thymidine counts for antigen-
stimulated and unstimulated cultures.Acknowledgments
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